{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-obstructive-pulmonary-disease/prescribing-information/muscarinic-antagonists/","result":{"pageContext":{"chapter":{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists","depth":2,"htmlHeader":"<!-- begin field 42e5d2ef-b60b-4054-8e32-c474129dd848 --><h2>Muscarinic antagonists</h2><!-- end field 42e5d2ef-b60b-4054-8e32-c474129dd848 -->","summary":"","htmlStringContent":"<!-- begin item 8ea94b93-dc8a-4e25-b089-cb67967f3285 --><!-- begin field 998be689-b4c4-4c9f-9817-61e5d561a952 --><ul><li>Muscarinic antagonists (also called antimuscarinic bronchodilators) cause bronchodilation by blocking the bronchoconstrictor effect of acetylcholine on muscarinic receptors in airway smooth muscle.</li><li>Ipratropium is a short-acting muscarinic antagonist (SAMA) which can be used for short-term relief in mild COPD in people who are not using a long-acting antimuscarinic drug. It has a slower onset of action than SABAs with maximal effect occurring 30–60 minutes after use — duration of action is 3–6 hours.</li><li>Long-acting muscarinic antagonists (LAMAs) such as tiotropium have prolonged binding to muscarinic receptors which lengthens the duration of bronchodilator effect.<ul><li>Aclidinium bromide, glycopyrronium bromide, and umeclidinium are LAMAs licensed for the maintenance treatment of adults with COPD — however, they are 'black triangle' drugs subject to intense surveillance by the Medicines and Healthcare products Regulatory Agency (MHRA).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 998be689-b4c4-4c9f-9817-61e5d561a952 --><!-- end item 8ea94b93-dc8a-4e25-b089-cb67967f3285 -->","topic":{"id":"8e2a563d-c3b1-5ed5-a460-de2b3ffc8c0f","topicId":"e48489e8-63d1-4a04-bc5b-07e36a76af58","topicName":"Chronic obstructive pulmonary disease","slug":"chronic-obstructive-pulmonary-disease","lastRevised":"Last revised in October 2020","chapters":[{"id":"8441dfb8-d2f6-511c-abf6-23d0c8a600d0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ccd2981-1bc9-5357-86d2-cbf578b57adb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2eb66d0c-0e3f-55c2-bb2f-ba47fdbd1bfd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8f4eeb38-3744-5824-a90c-82b0b8906580","slug":"changes","fullItemName":"Changes"},{"id":"f2cfeec1-2d2a-5d22-b569-42eb61ba7caa","slug":"update","fullItemName":"Update"}]},{"id":"d28cbe2c-ffc9-58ab-913c-3afa52c28841","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"99f07881-2c1a-5874-8cd2-3f10dcb385fa","slug":"goals","fullItemName":"Goals"},{"id":"85c2e06f-fe1e-532b-8752-0337ca19cfe3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f6fa4f07-a45d-5c3e-8c59-2054ea5ecd38","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"defe1786-7b6d-5c90-a7f4-0871262dd84f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"e6356570-e32f-5480-89d6-026b80bb055d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0433c46f-8e2f-53b3-a392-aca635b35160","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"29a2fdef-c0c3-5bb6-9c12-21d649ed27bb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"715af617-76e1-5846-9262-1616f0003270","slug":"definition","fullItemName":"Definition"},{"id":"6f383baf-ff39-58db-b933-24b4c5feb5f8","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"7fe9ff8f-68ba-5f97-91ab-8d23c907b1cf","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4bcdbaec-2487-5733-812a-7ec514939f8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c7c94e20-91a7-5b3d-b8dd-0d4f8d5c023c","slug":"complications","fullItemName":"Complications"}]},{"id":"844f6e5f-bd6a-5d1d-8f3e-0980e52cd744","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"aa2453ae-c791-521b-9ead-ca40d5efae00","slug":"diagnosis-copd","fullItemName":"Diagnosis - COPD"},{"id":"93fac9cc-fc19-5440-8330-f6f56941ddb6","slug":"diagnosis-acute-exacerbation","fullItemName":"Diagnosis - acute exacerbation"}]},{"id":"b513a018-d7cf-53a1-9748-c7fa367312d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"4aafe1b6-b17a-51d8-a8f0-104880ac3722","slug":"stable-copd","fullItemName":"Scenario: Stable COPD"},{"id":"ef02510d-99b8-561a-b40c-8bfaab787b88","slug":"acute-exacerbation","fullItemName":"Scenario: Acute exacerbation"},{"id":"22cd95c6-b76a-5e58-8329-cfed9e9bf26e","slug":"end-stage-copd","fullItemName":"Scenario: End-stage COPD"},{"id":"f1d4be42-b98a-55de-860a-3be931c97c1c","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"651db25c-bc72-5eaa-b790-e5c86053d13c","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"51f6354b-2f19-59ca-889c-a9497e0223fc","slug":"muscarinic-antagonists","fullItemName":"Muscarinic antagonists"},{"id":"10bec3db-4371-5d92-a5e9-4f2300029732","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"f45aa048-e0b1-55dc-9f40-68f5af6d3b61","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"1f101b12-c624-5d0c-9b55-c7fa2d40a3ed","slug":"mucolytics","fullItemName":"Mucolytics"},{"id":"669a5030-cc7b-5a64-ba03-f05ca2dd60f3","slug":"theophylline","fullItemName":"Theophylline"},{"id":"2006f9b1-cca0-50cd-9c1e-99a6316048e4","slug":"antibiotics","fullItemName":"Antibiotics"}]},{"id":"81fd9c2f-91c3-5726-b50a-85fc169646d3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b91263e-7dc1-51aa-9976-bd92619d846e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ac29e092-9d36-550e-99e2-c6b478d21c00","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"737d1a20-607a-560b-8522-2ddb2237249b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bec938e3-108f-5f91-9c9b-2c289bae4e07","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dc4c2f7c-85ce-5ba5-a2ef-149ee8a9d54d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51ecdba0-ee93-5792-af12-b38cb8f06b8c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9ad1cd46-bf5b-505f-a6d9-bad7287adccc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6e9178ad-4f96-5153-b348-f5f0f9132463","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0e353478-dc01-5513-a78e-3ed3a3289e6a","slug":"dose-of-short-acting","fullItemName":"Dose of short-acting","depth":3,"htmlHeader":"<!-- begin field 39d5895b-86da-4be4-8736-80b63def9b8c --><h3>Which short-acting muscarinic antagonists are available for COPD, and what doses should I prescribe?</h3><!-- end field 39d5895b-86da-4be4-8736-80b63def9b8c -->","summary":"","htmlStringContent":"<!-- begin item 35231ac0-da7b-4e81-a099-a2790cb48702 --><!-- begin field 84628ec4-781a-4255-8342-96ff9c884f2f --><ul><li><strong>Ipratropium</strong><ul><li>Aerosol inhalation — usually 20–40 micrograms (1–2 puffs), three or four times daily.</li><li>Nebulized solution — 250–500 micrograms three to four times daily.<ul><li>If dilution is necessary, use sterile sodium chloride 0.9%.</li></ul></li><li>Recommended doses may vary slightly for the different brands available. Doses for specific brands can be found in the BNF and the manufacturers' Summaries of Product Characteristics.</li></ul></li><li><strong>Combination products</strong><ul><li>Ipratropium with salbutamol — by inhalation of nebulised solution for bronchospasm in COPD (ipratropium bromide 500 micrograms plus salbutamol 2.5 mg) — 0.5/2.5 mg three or four times daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 84628ec4-781a-4255-8342-96ff9c884f2f --><!-- end item 35231ac0-da7b-4e81-a099-a2790cb48702 -->","subChapters":[]},{"id":"749520ac-cd3b-5643-b36d-b70306e5d3c7","slug":"dose-of-long-acting","fullItemName":"Dose of long-acting","depth":3,"htmlHeader":"<!-- begin field b8847461-b133-4a4d-98e4-4a8f3cfd88e6 --><h3>Which long-acting muscarinic antagonists are available for COPD, and what doses should I prescribe?</h3><!-- end field b8847461-b133-4a4d-98e4-4a8f3cfd88e6 -->","summary":"","htmlStringContent":"<!-- begin item 032dc7e7-8295-4103-a190-ed26ce29f957 --><!-- begin field 8d0735f2-1be9-4b6f-ad75-bf0dca554d0c --><ul><li><strong>Tiotropium </strong>— for maintenance treatment of COPD.<ul><li>For Spiriva® inhalation powder, 1 capsule contains a metered-dose of 18 micrograms tiotropium; for Braltus® inhalation powder, 1 capsule contains a metered-dose of 13 micrograms tiotropium.<ul><li>The delivered dose of Spiriva® and Braltus® inhalation powder products are the same (10 micrograms); no dose adjustment is necessary when switching between brands.</li></ul></li><li>For Spiriva Respimat® 5 micrograms once daily by inhalation of aerosol (2 puffs is equivalent to 5 micrograms of tiotropium).</li></ul></li><li><strong>Aclidinium, glycopyrronium and umeclidinium</strong> are licensed for the maintenance treatment of COPD. They are 'black triangle' drugs subject to intense surveillance by the Medicines and Healthcare products Regulatory Agency (MHRA).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 8d0735f2-1be9-4b6f-ad75-bf0dca554d0c --><!-- end item 032dc7e7-8295-4103-a190-ed26ce29f957 -->","subChapters":[]},{"id":"af1c48a2-3616-535a-85d2-c9035bb968f3","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field 9fa59a53-a8cf-4c95-8bf5-18e7a0d61448 --><h3>When should antimuscarinics be used with caution?</h3><!-- end field 9fa59a53-a8cf-4c95-8bf5-18e7a0d61448 -->","summary":"","htmlStringContent":"<!-- begin item 379718a1-f536-4f6d-831a-879071410acf --><!-- begin field 089a6378-02bb-420c-91d8-04b55d67d325 --><ul><li><strong>Antimuscarinics should be used with caution in:</strong><ul><li>Men with prostatic hyperplasia and bladder-outflow obstruction — worsened urinary retention has been reported in elderly men.</li><li>People with renal impairment — manufacturer advises use only if potential benefit outweighs risk if creatinine clearance less than or equal to 50 mL/minute.</li><li>People with angle-closure glaucoma — nebulized mist of antimuscarinic drugs can precipitate or worsen acute angle-closure glaucoma.</li><li>Pregnancy or breastfeeding — manufacturer recommends avoid, seek specialist advice.</li></ul></li><li>Tiotropium should be used with caution in people with cardiac arrhythmias, heart failure or myocardial infarction in the previous 6 months.<ul><li>There is an increased risk of all-cause mortality in this group of people following the use of this product.</li></ul></li><li><strong>Combination ipratropium with salbutamol </strong>is contraindicated in people with hypertrophic obstructive cardio- myopathy or tachyarrhythmia — see section on Beta-2 agonists for additional information.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">MHRA, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 089a6378-02bb-420c-91d8-04b55d67d325 --><!-- end item 379718a1-f536-4f6d-831a-879071410acf -->","subChapters":[]},{"id":"2fe2e1f1-2867-5a4f-9b44-b74c2297aa33","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field dc6d3c88-1dce-495a-a449-6e76085c5fab --><h3>What are the adverse effects of antimuscarinics?</h3><!-- end field dc6d3c88-1dce-495a-a449-6e76085c5fab -->","summary":"","htmlStringContent":"<!-- begin item 8f703e12-873a-4e93-b7e4-9d0fad884617 --><!-- begin field 4836bbf9-5b03-424a-b858-6ef0213cfdc4 --><ul><li>The adverse effects of antimuscarinics include:<ul><li>Cardiac disorders such as arrhythmias and palpitations.</li><li>Respiratory disorders such as paradoxical bronchospasm, throat irritation, and cough.</li><li>Gastrointestinal disorders such as dry mouth, abnormal taste in the mouth, nausea, vomiting, constipation and diarrhoea.</li><li>ENT disorders such as nasal congestion, dryness of nasal mucosa, and epistaxis.</li><li>Nervous system disorders such as headache and dizziness.</li><li>Urinary disorders such as bladder outflow obstruction and prostatic hyperplasia.</li><li>Visual disorders including acute angle-closure glaucoma — reported in people on nebulized ipratropium, particularly when given with nebulised salbutamol. To reduce the risk of this adverse effect, advise people:<ul><li>To use a mouthpiece rather than a mask with a nebulizer, if possible, to minimize exposure of the eyes to the drug.</li><li>On correct administration of dry powder and aerosol inhalers to avoid accidental release of the contents into the eye.</li><li>With angle-closure glaucoma who are using muscarinic antagonists to stop and consult a specialist immediately if they experience eye pain or discomfort, visual halos or coloured images, or temporary blurring of vision.</li></ul></li></ul></li><li>Risk of airway obstruction from aspiration of loose objects with pressurised metered-dose inhalers.<ul><li>The MHRA has received reports of cases where a Braltus® capsule has been inhaled from the mouthpiece into the back of the throat, resulting in coughing and risking aspiration or airway obstruction. Patients should be trained in the correct use of their inhaler and told to store capsules in the screw-top bottle provided (never in the inhaler) and to always check the mouthpiece is clear before inhaling.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">MHRA, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">GOLD, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>]</p><!-- end field 4836bbf9-5b03-424a-b858-6ef0213cfdc4 --><!-- end item 8f703e12-873a-4e93-b7e4-9d0fad884617 -->","subChapters":[]},{"id":"9c66231b-0a84-5fa7-a19c-341187f3d45a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ffb9b148-cf27-41d9-95b8-5100fd02ab87 --><h3>What drug interactions are important with muscarinic antagonists?</h3><!-- end field ffb9b148-cf27-41d9-95b8-5100fd02ab87 -->","summary":"","htmlStringContent":"<!-- begin item 14144418-ecde-41e7-b97d-0866c4dd0d11 --><!-- begin field fad7cd75-1d9c-4972-ae41-a5786018559d --><ul><li>Concurrent use of inhaled antimuscarinics with other antimuscarinic drugs is not recommended as the effects of concurrent use have not been studied.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2018n</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">ABPI, 2019a</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-obstructive-pulmonary-disease/references/\">BNF, 2019</a>] </p><!-- end field fad7cd75-1d9c-4972-ae41-a5786018559d --><!-- end item 14144418-ecde-41e7-b97d-0866c4dd0d11 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}